aripiprazole / Generic mfg. - LARVOL DELTA

Gaps in the detection of drug-drug interactions between antipsychotic and cardiometabolic medications: a multisource analysis. (PubMed, BMC Med) - "This systematic review and disproportionality analysis identified potential DDIs between antipsychotic medications and cardiometabolic medications, many of which were not captured by commonly used DDI checkers. These findings underscore the need for clinicians to consult multiple sources and apply clinical judgment when prescribing these medications. Improved integration of pharmacovigilance data into DDI checkers may enhance the identification and prevention of harmful interactions."

Journal • Cardiovascular • CNS Disorders • Gastroenterology • Gastrointestinal Disorder • Metabolic Disorders • Musculoskeletal Diseases • Rheumatology

Update on tic disorders and Tourette syndrome (PubMed, Nervenarzt) - "Pharmacological treatment includes off-label use of dopamine antagonists, such as aripiprazole. Comorbidities are common and require targeted comanagement."

Journal • CNS Disorders • Developmental Disorders • Movement Disorders • Psychiatry • Tic Disorders • Tourette Syndrome

Managing treatment-resistant schizophrenia following clozapine cessation: a case report of xanomeline-trospium and olanzapine combination therapy. (PubMed, Front Psychiatry) - "Aripiprazole, titrated to 15 mg/day, and subsequent augmentation with olanzapine failed to restore stability. Clozapine-related VTE/PE represents a serious clinical dilemma. This case illustrates the potential of muscarinic-dopaminergic strategies to restore stability in TRS when clozapine is no longer an option."

Journal • Cardiovascular • CNS Disorders • Epilepsy • Hematological Disorders • Psychiatry • Respiratory Diseases • Schizophrenia • Venous Thromboembolism

Isolated neck tremor as a rare tardive effect of long-term aripiprazole therapy. (PubMed, J Gen Fam Med) - No abstract available

Journal • Movement Disorders

Distinct functional profiles of partial agonist antipsychotics in cAMP and β-arrestin signaling mechanisms of dopamine D2 and D3 receptors in vitro. (PubMed, Prog Neuropsychopharmacol Biol Psychiatry) - "While cariprazine showed partial agonism and partial antagonism at D3 receptor-mediated β-arrestin translocation, aripiprazole and brexpiprazole displayed only weak or no agonist but potent antagonist activity. These data suggest differentiated mechanism of action of cariprazine at the D3 receptor signaling compared to aripiprazole and brexpiprazole."

Journal • Preclinical • CNS Disorders

Impact of selected second and third generation antipsychotics on cognitive dysfunction in schizophrenia-spectrum disorders. Systematic review and network meta-analysis. (PubMed, Int Clin Psychopharmacol) - "This study aimed to: (a) systematically review randomized controlled trials (RCTs) evaluating the cognitive effects of third-generation antipsychotics (TGAs: brexpiprazole, cariprazine, lumateperone, and lurasidone) and xanomeline-trospium; and (b) perform a network meta-analysis (NMA) including additional second-generation antipsychotics with potential procognitive effects. A systematic literature search identified eligible RCTs, which were combined with trials on aripiprazole, olanzapine, quetiapine, risperidone, and ziprasidone from a previous meta-analysis...In conclusion, selected second and TGAs, including M1/M4 receptor agonists such as xanomeline, may offer promising treatment options for cognitive dysfunction. Further research should personalize pharmacological strategies based on cognitive profiles."

Journal • Retrospective data • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Cognitive Disorders • Psychiatry • Schizophrenia

A Diagnostic Dilemma-Severe Hyperthermia and Rigidity in a Young Man with Polysubstance Use: A Case Report. (PubMed, Clin Pract Cases Emerg Med) - "This case underscores the importance of considering neuroleptic malignant syndrome in patients with atypical presentations, suspicion for comorbid psychiatric conditions, and substance use disorder. Timely diagnosis, discontinuation of the offending agent, and targeted therapies such as dantrolene are critical in preventing complications. We highlight the diagnostic challenges and management strategies for NMS in the context of a limited history and severe hyperthermia."

Journal • Anesthesia • Cardiovascular • CNS Disorders • Critical care • Immunology • Metabolic Disorders • Psychiatry • Schizophrenia • Systemic Inflammatory Response Syndrome

Prevention of prolactin reduction: a novel strategy countering multi-generational growth retardation caused by maternal exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. (PubMed, J Toxicol Sci) - "Aripiprazole (ARI), a partial dopamine D2 receptor (D2R) agonist, increases PRL levels by inhibiting the effect of dopamine during PRL synthesis and secretion. Importantly, administration of ARI to F0 dams not only restored PRL levels, nursing behavior, and milk volume in the treated mothers but also mitigated the developmental deficits observed in F2/F3 offspring. These findings highlight the critical role of PRL in maternal care and offspring development and suggest that ARI could be a potential therapeutic intervention to mitigate the effects of TCDD-induced multi-generational developmental disruptions."

Journal • CNS Disorders • Developmental Disorders • Psychiatry • DRD2 • PRL

Behavioral and pharmacological intervention in autism spectrum disorder: CARS score changes across cognitive levels. (PubMed, Tzu Chi Med J) - "This study aimed to investigate the core symptom of autism in Indonesian children using Childhood Autism Rating Scale (CARS) scores and their relationship with cognitive profiles while evaluating the effectiveness of aripiprazole and behavioral intervention across different cognitive levels...Early identification, accurate differentiation between LC-ASD and HC-ASD, and targeted interventions combining pharmacological treatment with BT are essential for improving outcomes in children with ASD. These approaches can reduce symptom complexity while fostering long-term functional skills development."

Clinical • Journal • Autism Spectrum Disorder • Genetic Disorders

A Severe Case of Drug-Induced Hypersensitivity Syndrome (DIHS) Presenting as Acute Liver Failure Requiring Urgent Liver Transplantation (ACG 2025) - "He was recently initiated aripiprazole and oral diclofenac 3 week prior.Initial labs showed AST 2687, ALT 1810, total bilirubin 14.8, INR 1.5 and renal failure...While eosinophilia is a hallmark feature, it may be absent initially in up to 31% of cases. This case emphasizes the need for early recognition of DIHS and the potential for severe outcomes requiring liver transplantation.Figure: Liver core needle biopsy demonstrating portal inflammation with bridging necrosis extending along the interface with the lobular parenchyma (H+E stain, 20X).Figure: Liver explant, demonstrating extensive inflammation and nodularity imparted by extensive bridging necrosis (H+E stain, 4X)"

Clinical • CNS Disorders • Eosinophilia • Fatigue • Hepatology • Immunology • Inflammation • Liver Failure • Musculoskeletal Pain • Renal Disease • Transplantation

Update on Pharmacology in Tourette's Disorder (AACAP 2025) - "There are only 3 pharmacological interventions FDA-approved for TD: pimozide, haloperidol, and aripiprazole, and as such, most treatments are used off-label...She will also describe recent trials that did not meet their primary end points (eg, deutetrabenazine, nabiximols), but may still hold promise for certain individuals/subgroups with TD... There is a great need for new medications for TD that are as effective for tics as antipsychotics, but without the potential short and long-term side effects associated with typical and atypical antipsychotics. Recently, new medications currently in Phase IIb and III trials are showing great promise!.TD, TICD, PPC"

CNS Disorders • Mental Retardation • Movement Disorders • Psychiatry • Tourette Syndrome

Long-Acting Injectable Antipsychotics in Adolescents With Bipolar Disorder (AACAP 2025) - "The LAI antipsychotics used included aripiprazole, paliperidone, and risperidone (at intervals of 1, 2, or 3 months). The mean YMRS score declined to 21.7 at 1 month, to 12.3 at 2 months, to 4.9 at 6 months, and to 3.0 at 1 year. Although LAI antipsychotics are not officially approved for patients under the age of 18 years, our compassionate off-use of LAI therapy in 116 adolescents at high risk for manic relapse demonstrated very good efficacy, tolerability, long-term clinical stability, and return to function.BRD, ADOL, AGG"

Bipolar Disorder • CNS Disorders • Cognitive Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry • Schizophrenia

Predictors of 12-Month Readmission Among Youth With Early Serious Mental Illness Treated With Long-Acting Injectable Antipsychotic Medications (AACAP 2025) - "LAI formulation (aripiprazole vs paliperidone/risperidone) and number of prior hospitalizations were not significant predictors of readmission. Among youth with early SMI treated with LAIs, younger age, lack of prior LAI exposure, and discharge to higher levels of outpatient care were associated with increased readmission risk. Among youth with early SMI treated with LAIs, younger age, lack of prior LAI exposure, and discharge to higher levels of outpatient care were associated with increased readmission risk. Which LAI was used did not appear to impact readmission risk in this sample, suggesting that both aripiprazole and paliperidone LAIs are appropriate choices in youth populations. These results can contribute to the development of future risk stratification frameworks and discharge protocols aimed at reducing rehospitalization and optimizing long-term outcomes in this vulnerable population.PSY, RF, TREAT"

CNS Disorders • Psychiatry

Comparison of Clinical Outcomes in Adolescents With Psychotic Symptoms Diagnosed With Bipolar Disorder and Schizophrenia (AACAP 2025) - "The most prescribed medications for BAD were aripiprazole (81.6%), quetiapine (65.8%), and lorazepam (65.8%), while for schizophrenia, they were lorazepam (41.7%), biperiden (41.7%), and paliperidone (37.5%). Although some differences were observed between the 2 groups—such as a higher prevalence of intellectual disability in patients with schizophrenia and variations in prescribed medications—most comparisons, including the number of hospitalizations and family history of mental disorders, did not reach statistical significance.SZ, APS, PSY"

Clinical • Clinical data • Bipolar Disorder • CNS Disorders • Depression • Developmental Disorders • Mental Retardation • Mood Disorders • Psychiatry • Schizophrenia

Longitudinal Effects of Antipsychotic Use on Clinical and Metabolic Measures in Children in the ABCD Cohort (AACAP 2025) - "A total of 178 children were prescribed a second-generation AP, with aripiprazole (n = 93) and risperidone (n = 62) being the most common. In this population-based cohort, 1.57% of children used antipsychotics on at least one visit between ages 9 and 14. Antipsychotic use was associated with significant symptom improvement, but also with a more rapid increase in BMI and WC. Given the notable use of antipsychotics in children and the associated metabolic risks, these findings underscore the need for well-controlled clinical studies to better guide antipsychotic use in pediatric populations.APS, ADOL, PSP"

Clinical • CNS Disorders • Pediatrics

Literature Review of the Use of Clozapine in Children With ASD for Behavioral Disturbances (AACAP 2025) - "One case describes an adolescent with ASD whose disruptive behaviors improved markedly on clozapine but subsequently developed compulsive behaviors that resolved with aripiprazole augmentation. Our literature review demonstrates that clozapine is an effective drug for behavioral disturbances in children and young adults with ASD. The limitations of our study include the lack of research on the use of clozapine in this patient population, specifically to limited data on its use and efficacy in marginalized populations. Further research is needed to address these deficiencies.ASD, APS, AGG"

Clinical • Review • Autism Spectrum Disorder • Behavior Disorders • CNS Disorders • Genetic Disorders • Mental Retardation • Psychiatry • Schizophrenia

Case Series: The Clinical Utility of Pharmacogenomic Testing in the Treatment of Difficult-to-Treat Mood, Behavior, and Psychotic Disorders in Children and Adolescents (AACAP 2025) - "Pharmacogenomic testing did not significantly improve clinical outcomes in a small sample of children and adolescents prescribed antipsychotics for difficult-to-treat mood, behavioral, and psychotic disorders. Given that evidence-based choices are currently limited to aripiprazole and risperidone for children and adolescents, it is unlikely that evolving recommendations will substantially change practice in the near term.PKS, PDS, TREAT"

Biomarker • Clinical • CNS Disorders • Psychiatry

Data Supporting Pharmacogenetic Applications in the Pharmacologic Treatment of Youth (AACAP 2025) - "Pharmacogenes are associated with PK and tolerability in youth treated with antidepressants and antipsychotics. Child and adolescent psychiatrists should know the evidence behind these studies as they consider the use of pharmacogenetic testing in their clinical practice.ADP, APS, PPC"

Biomarker • CNS Disorders • Pediatrics • Psychiatry • CYP2C19

AACAP 2025 George Tarjan, MD, Award for Contributions in Developmental Disabilities: Target Engagement Fast-Fail Clinical Trials in Neurodevelopmental Disorders (AACAP 2025) - "While this followed successful approvals of aripiprazole and risperidone as treatments of irritability in youth with autism, success has not followed from these early accomplishments. We are hopeful that our ability to better parse variation even in single-gene neurodevelopmental disorders will result in the personalization of medicine in this field, leading to success in treatment development.ND, PPC"

Clinical • Neurodevelopmental • Autism Spectrum Disorder • CNS Disorders • Developmental Disorders • Fragile X Syndrome • Genetic Disorders • Psychiatry

The Weight of Treatment: Addressing Antipsychotic-Induced Metabolic Risks (AACAP 2025) - "Youth are particularly at risk for antipsychotic-induced weight gain and obesity. Correll and colleagues showed in the SATIETY study that children and adolescents who are prescribed SGAs after 10 weeks gained significant weight, and that some antipsychotic medications have more impact than others (olanzapine 8.5 kg, quetiapine 1 kg, risperidone 4.4 kg, aripiprazole 0.2 kg). This presentation will focus on the metabolic burden of antipsychotic treatment in youth, including monitoring guidelines, and the rationale behind choosing SGAs when metabolic side effects emerge. It will provide an overview of evidence-based strategies to address metabolic side effects, with an emphasis on commonly and safely utilized psychopharmacological interventions such as metformin. The talk will also introduce behavioral treatments, as well as newer psychopharmacological agents, such as GLP-1 agonists.ADOL, APS, MAE"

CNS Disorders • Genetic Disorders • Obesity • Psychiatry

Pharmacogenetic Guidelines and Resources to Support Antidepressant and Antipsychotic Use in Child and Adolescent Psychiatry (AACAP 2025) - "The FDA categorizes drug-gene pairs by implications on therapeutic management, safety, or pharmacokinetics. If a patient has genotype results available, the CPIC and/or FDA currently provide assessments supporting the utility of PGx to inform the use of many antidepressants including es/citalopram (CYP2C19), fluvoxamine (CYP2D6), paroxetine (CYP2D6), sertraline (CYP2C19 and CYP2B6), TCAs (CYPC19 and/or CYP2D6), venlafaxine (CYP2D6), and vortioxetine (CYP2D6)...FDA labeling provides specific dosing based on CYP2D6 poor metabolizer genotypes for aripiprazole, brexpiprazole, iloperidone, pimozide, and thioridazine... CPIC and FDA resources are useful for identifying evidence-based PGx information for commonly used antidepressants and antipsychotics. PharmGKB and Sequence2Script support access to foundational literature and the clinical implementation of PGx results.PPC, ADP, APS"

Biomarker • Clinical • CNS Disorders • Psychiatry • CYP19A1 • CYP2C19 • HTR2A • SLC6A4

Sexual reactivation under aripiprazole in schizophrenia: a note for prescribers. (PubMed, J Psychiatry Neurosci) - No abstract available

Journal • CNS Disorders • Psychiatry • Schizophrenia

Drug-induced movement disorder: A disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2004 to 2024. (PubMed, PLoS One) - "Our disproportionality analysis and sensitivity analysis of the FAERS database identified drugs potentially associated with DIMDs. These findings can provide valuable information for clinicians to be more cautious when prescribing these drugs and to monitor patients for the development of movement disorders closely. Additionally, the results can help regulatory agencies make informed decisions regarding the safety of drugs."

Adverse events • Journal • Movement Disorders

Clinical study of low dose aripiprazole plus Minapram in the treatment of depression (ChiCTR) - P4 | N=90 | Recruiting | Sponsor: Jingzhou mental health center; Jingzhou mental health center

New P4 trial • CNS Disorders • Depression • Mood Disorders • Psychiatry

The Efficacy and Safety of Bumetanide in Children with Autism Spectrum Disorder: An Updated Meta-analysis. (PubMed, Eur Child Adolesc Psychiatry) - "The treatment of ASD is challenging since there are no approved drugs except for risperidone and aripiprazole, which have a limited effect on core symptoms and are associated with a wide range of adverse events. Common adverse events include polyurea, hypokalemia, and dehydration. Although statistically significant improvements were observed on some measures, we cannot conclude the superiority of bumetanide in alleviating ASD symptoms. Further large clinical trials should be conducted to determine the effect of bumetanide on different symptoms of ASD and the variation in treatment effect among different patient populations."

Journal • Retrospective data • Review • Autism Spectrum Disorder • CNS Disorders • Developmental Disorders • Genetic Disorders • Psychiatry